Plaque psoriasis is the most common form of psoriasis, a chronic immune-mediated inflammatory skin disease affecting approximately 2–3% of the global population. Biologics targeting IL-17, IL-23, and TNF have transformed outcomes for moderate-to-severe disease, with high rates of skin clearance now achievable. Oral TYK2 inhibitors represent the newest mechanism and the first oral targeted therapy to achieve PASI 90 response rates comparable to biologics.
GLP-1 Receptor Agonists and Psoriatic Disease: A Deep Dive
GLP-1 receptor agonists, primarily for type 2 diabetes and obesity, show emerging evidence for modifying psoriatic disease activity.
Psoriasis Workup Expands Beyond Skin: SDPA 2026 Highlights Systemic Risk
Psoriasis management is evolving, with new guidance emphasizing systemic comorbidities beyond dermatological manifestations.
Psoriasis Patients Report Chronic Intense Pain, Multiple Pain Sites
Psoriasis is associated with chronic intense pain and a higher prevalence of multiple pain sites, impacting patient quality of life.
Is It Safe To Switch Biosimilars?
The NOR-SWITCH trial established that switching from reference infliximab to a biosimilar is safe. Multiple subsequent studies have confirmed this across adalimumab and other biologics. Sarah Mitchell and James Carter examine the switching evidence, the noc...
Why Half Of Psoriasis Patients Quit
Up to half of psoriasis patients discontinue their treatment within a year. The reasons are complex — side effect fear, injection fatigue, visible improvement masking ongoing disease — and the solutions require as much psychology as pharmacology. Sarah Mitc...
Psoriasis Monitoring Landscape Guide
Monitoring for methotrexate-related liver toxicity dominated psoriasis practice for decades — now the PIIINP blood test has replaced routine liver biopsies in most guidelines. Sarah Mitchell and James Carter walk through the current monitoring framework for...
Replacing Biologic Injections With Oral Pills
Deucravacitinib — the first approved TYK2 inhibitor — offers a new oral option for moderate-to-severe psoriasis without the cardiovascular safety concerns attached to pan-JAK inhibitors. Sarah Mitchell and James Carter examine how the oral therapy landscape...
Biologics Offer Targeted Efficacy in Psoriasis Management
Biologic therapies have significantly advanced psoriasis treatment by targeting specific immune pathways, offering improved outcomes for patients.